Home › Research › Treatments
Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis
Nakai, T.; Koseki, T.; Watanabe, H.; Yamada, S.. medRxiv (preprint), 2026-09-11
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BackgroundAnti-amyloid-{beta} (A{beta}) monoclonal antibodies are disease-modifying treatments for early Alzheimers disease but are associated with amyloid-related imaging abnormalities (ARIA) and intracranial hemorrhage (ICH). However, the safety of concomitant antithrombotic use remains unclear. ObjectiveTo evaluate potential drug-drug interaction (DDI) signals between anti-A{beta} antibodies and antithrombotic drugs for ARIA and ICH using the FDA Adverse Event Reporting System (FAERS; JAPIC AERS). MethodsFAERS reports from 1997 to 2024 were analyzed. The anti-A{beta} antibodies evaluated were aducanumab, lecanemab, and donanemab. Antithrombotics were aspirin, P2Y12 inhibitors, direct oral anticoagulants, warfarin, and tissue-type plasminogen activators (tPAs). Outcomes were any ARIA, ARIA with edema or effusion (ARIA-E), ARIA with hemosiderin deposition (ARIA-H), and ICH. Individual-drug signals were assessed using reporting odds ratios and information components; DDIs were evaluated using four complementary models. ResultsAll three antibodies showed positive signals for all outcomes. When the three antibodies were analyzed together, aspirin showed positive DDI signals for any ARIA, ARIA-E, and ARIA-H in three models. Lecanemab-aspirin also showed signals for any ARIA and ARIA-H in multiple models. For ICH, tPAs showed signals in all four models with lecanemab and in the analysis combining all anti-A{beta} antibodies. Both analyses were based on the same five lecanemab reports. ConclusionsDDI signals were detected for anti-A{beta} antibody-aspirin combinations for ARIA and anti-A{beta} antibody-tPA combinations for ICH, particularly with lecanemab. These findings may warrant careful review of aspirin indications and baseline hemorrhagic risk and caution with thrombolysis during anti-A{beta} antibody treatment, although prospective validation is needed.
What this study adds
Evidence grade: Low
This analysis of adverse event reports found potential drug-drug interaction signals between anti-amyloid-β antibodies and antithrombotic drugs for amyloid-related imaging abnormalities and intracranial hemorrhage. It suggests caution with aspirin and thrombolysis during antibody treatment, but prospective validation is needed and it is not about curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nakai, T., Koseki, T., Watanabe, H., & Yamada, S. (2026). Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis. medRxiv (preprint). https://doi.org/10.64898/2026.09.08.26362402
Vancouver
Nakai T, Koseki T, Watanabe H, Yamada S. Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis. medRxiv (preprint). 2026. doi:10.64898/2026.09.08.26362402.
BibTeX
@article{nakai2026-ba303595,
author = {Nakai, T. and Koseki, T. and Watanabe, H. and Yamada, S.},
title = {{Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis}},
journal = {medRxiv (preprint)},
year = {2026},
doi = {10.64898/2026.09.08.26362402},
url = {https://doi.org/10.64898/2026.09.08.26362402}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- BackgroundAnti-amyloid-{beta} (A{beta}) monoclonal antibodies are disease-modifying treatments for early Alzheimers disease but are associated with amyloid-related imaging abnormalities (ARIA) and intracranial hemorrhage (ICH).
- These findings may warrant careful review of aspirin indications and baseline hemorrhagic risk and caution with thrombolysis during anti-A{beta} antibody treatment, although prospective validation is needed.
Why it matters
This analysis of adverse event reports found potential drug-drug interaction signals between anti-amyloid-β antibodies and antithrombotic drugs for amyloid-related imaging abnormalities and intracranial hemorrhage. It suggests caution with aspirin and thrombolysis during antibody treatment, but prospective validation is needed and it is not about curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 18 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 17 of the 94 points we could judge it on, which is 18 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv (preprint)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Shigeki Yamada: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Fujita Health University: institution h-index 344 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 17 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 17 of the 94 points we could judge it on is 18 out of 100. |
| Total | 18 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.